These experiences underscore the need for biomarker-gated eligibility, combination designs (e.g., CXCR4 blockade to disrupt CXCL12-mediated exclusion), and careful on-target/off-tumor safety monitoring when engaging broadly expressed stromal markers. Here, CXCL12 is linked to neoplasm.